Telino E, De Luca P M, Matos D C S, Azeredo-Coutinho R B, Meirelles M N, Conceição-Silva F, Schubach A, Mendonça S C F
Department of Immunology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Clin Exp Immunol. 2006 Feb;143(2):338-44. doi: 10.1111/j.1365-2249.2006.02995.x.
Whole-cell and soluble extracts of Leishmania promastigotes have both been used as skin test antigens and have also been tested as vaccine candidates. However, the differences in antigenicity between soluble and particulate Leishmania fractions are not known. We evaluated in vitro responses of PBMC from 30 American tegumentary leishmaniasis (ATL) patients and seven noninfected donors to different antigen preparations from Leishmania promastigotes, namely Leishmania amazonensis and L. braziliensis whole-cell extracts, as well as soluble and particulate fractions of L. amazonensis. All Leishmania antigen preparations stimulated significantly higher proliferation and interferon (IFN)-gamma production (but not interleukin (IL)-10 production) in PBMC from the leishmaniasis patients than in cells from the control subjects. The L. braziliensis whole-cell extract stimulated significantly higher cell proliferation and IFN-gamma production than the L. amazonensis whole-cell extract in the group of patients but not in the control group. This result can be explained by the fact that the patients were infected with L. braziliensis. Again in the group of patients, the PBMC proliferative responses as well as the levels of IFN-gamma and IL-10 stimulated by L. amazonensis whole-cell extract were significantly greater than those elicited by the L. amazonensis soluble fraction but were not significantly different from those elicited by the L. amazonensis particulate fraction. We found a higher antigenicity of the particulate fraction as compared to the soluble fraction, what suggests that the antigens present in the particulate fraction account for most of the antigenicity of whole-cell Leishmania promastigote antigen extracts.
利什曼原虫前鞭毛体的全细胞提取物和可溶性提取物都已被用作皮肤试验抗原,并且也作为候选疫苗进行了测试。然而,可溶性和颗粒性利什曼原虫组分之间的抗原性差异尚不清楚。我们评估了30名美洲皮肤利什曼病(ATL)患者和7名未感染供体的外周血单核细胞(PBMC)对来自亚马逊利什曼原虫和巴西利什曼原虫前鞭毛体的不同抗原制剂的体外反应,即亚马逊利什曼原虫和巴西利什曼原虫的全细胞提取物,以及亚马逊利什曼原虫的可溶性和颗粒性组分。与对照组细胞相比,所有利什曼原虫抗原制剂均能显著刺激利什曼病患者PBMC中更高的增殖和干扰素(IFN)-γ产生(但不刺激白细胞介素(IL)-10产生)。在患者组中,巴西利什曼原虫全细胞提取物刺激的细胞增殖和IFN-γ产生显著高于亚马逊利什曼原虫全细胞提取物,但在对照组中并非如此。这一结果可以用患者感染了巴西利什曼原虫这一事实来解释。同样在患者组中,亚马逊利什曼原虫全细胞提取物刺激的PBMC增殖反应以及IFN-γ和IL-10水平显著高于亚马逊利什曼原虫可溶性组分刺激的反应,但与亚马逊利什曼原虫颗粒性组分刺激的反应无显著差异。我们发现颗粒性组分的抗原性高于可溶性组分,这表明颗粒性组分中存在的抗原占利什曼原虫前鞭毛体全细胞抗原提取物大部分的抗原性。